Becton, Dickinson and Company (BMV:BDX)
Mexico
· Delayed Price · Currency is MXN 3,319.20
-728.66 (-18.00%)
At close: May 14, 2025
Revenue by Product
Fiscal year is October - September.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | 2012 - 2020 |
| Medication Delivery Solutions | 4.51B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Medication Delivery Solutions Growth | 3.87% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharmaceutical Systems | 2.26B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharmaceutical Systems Growth | 0.44% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Integrated Diagnostic Solutions | 3.67B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Integrated Diagnostic Solutions Growth | 1.30% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biosciences | 1.47B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biosciences Growth | -3.41% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Medication Management Solutions | 3.39B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Medication Management Solutions Growth | 10.49% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Surgery | 1.52B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Surgery Growth | 1.33% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Peripheral Intervention | 1.94B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Peripheral Intervention Growth | 1.99% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Urology and Critical Care | 1.55B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Urology and Critical Care Growth | 4.09% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Medical | 10.77B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Medical Growth | 11.41% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Life Sciences | 5.14B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Life Sciences Growth | -0.08% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Interventional | 5.02B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Interventional Growth | 2.45% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBIT by Product
Fiscal year is October - September.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | 2012 - 2020 |
| Medical Operating Income | 2.59B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Medical Operating Income Growth | 31.39% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Life Sciences Operating Income | 1.57B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Life Sciences Operating Income Growth | 1.55% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Interventional Operating Income | 1.52B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Interventional Operating Income Growth | 17.19% |
Log In |
Log In |
Log In |
Log In | Upgrade
|